The relative efficacy, safety and ecological implications of macrolides vs. quinolones in the
treatment of community-acquired pneumonia (CAP) are debatable. We performed a …

Background: Anti-pneumococcal fluoroquinolone has been used to treat communityacquired
pneumonia (CAP) frequently because of its broad antimicrobial spectrum. Methods: This …

Background: The conventional treatment for community-acquired pneumonia (CAP) involves
combination therapy consisting of a β-lactam penicillin or a cephalosporin with a macrolide …

Materials and Methods: Patients with mild to moderate CAP were randomized into two
groups. Group I received a combination of 1 gram ceftriaxone daily and 500 mg azithromycin …

The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the
most ardently debated issues in medicine. Presently, most guidelines recommend either a …

Objective: This study aimed to compare the efficacy and safety of oral gemifloxacin, an
enhanced-affinity quinolone, with sequential therapy with IV ceftriaxone followed by oral …

Background: Changing etiologic patterns and the growing problem of antimicrobial
resistance, particularly an increase in macrolide-resistant pneumococcal bacteremia, are …

Background To determine the cost-effectiveness of strategies of preferred antibiotic
treatment with beta-lactam/macrolide combination or fluoroquinolone monotherapy …

Background: For the empirical treatment of communityacquired pneumonia requiring
admission to a non-ICU ward, the Dutch guidelines recommend either beta-lactam …

The four major factors predisposing individuals to community-acquired pneumonia (CAP)
are chronic obstructive pulmonary disease, congestive heart failure, diabetes, and a high …